Lidiya Bebrevska
Basel, BS, Switzerland
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 11 publications
Drug-drug interactions of icenticaftor (QBW251) with a 5-probe cytochrome P450 cocktail and oral contraceptives.
Journal: Clinical and translational science
Published: May 14, 2024
Absorption, Distribution, Metabolism, and Excretion of Icenticaftor (QBW251) in Healthy Male Volunteers at Steady State and In Vitro Phenotyping of Major Metabolites.
Journal: Drug metabolism and disposition: the biological fate of chemicals
Published: April 09, 2024
Concentration-QTcF Modeling of Icenticaftor from a Randomized, Placebo- and Positive-Controlled Thorough QT Study in Healthy Participants.
Journal: Clinical pharmacology in drug development
Published: October 17, 2023
Relative Bioavailability and Food Effect of Asciminib Pediatric Mini-tablet Formulation Compared to the Reference Tablet Formulation in Healthy Adult Participants.
Journal: Clinical pharmacology in drug development
Published: September 22, 2022
Combining SJ733, an oral ATP4 inhibitor of Plasmodium falciparum, with the pharmacokinetic enhancer cobicistat: An innovative approach in antimalarial drug development.
Journal: EBioMedicine
Published: January 13, 2022
An innovative study design with intermittent dosing to generate a GLP-regulatory package in preclinical species for long lasting molecule M5717, inhibitor of Plasmodium eukaryotic translation elongation factor 2.
Journal: Toxicology and applied pharmacology
Published: December 15, 2021
The antimalarial MMV688533 provides potential for single-dose cures with a high barrier to Plasmodium falciparum parasite resistance.
Journal: Science translational medicine
Published: January 15, 2021
Safety, tolerability, pharmacokinetics, and antimalarial efficacy of a novel Plasmodium falciparum ATP4 inhibitor SJ733: a first-in-human and induced blood-stage malaria phase 1a/b trial.
Journal: The Lancet. Infectious diseases
Published: June 12, 2019
Safety, tolerability, pharmacokinetics, and activity of the novel long-acting antimalarial DSM265: a two-part first-in-human phase 1a/1b randomised study.
Journal: The Lancet. Infectious diseases
Published: December 22, 2016
Corrigendum: A novel multiple-stage antimalarial agent that inhibits protein synthesis.
Journal: Nature
Published: June 10, 2016
A novel multiple-stage antimalarial agent that inhibits protein synthesis.
Journal: Nature
Published: October 10, 2014
Showing 1-11 of 11
Last Updated: 09/26/2026